Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress. “We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT,” said Mark Rutstein, MD, Global Head, Oncology Development, Novartis. “With a legacy of bold science, our Kisqali and Scemblix data offer continued evidence of how we meaningfully move cancer treatment forward for patients.” Key ASCO data highlights include: Abstract Title Abstract Number/ Presentation Details Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Subgroup Analyses by Disease Volume and De Novo/Recurrent mHSPC in the PSMAddition Study of [ 177 Lu]Lu-PSMA-617 225 Ac-PSMA-617 AcTION: Phase 1 Study of [ 225 Ac]Ac-PSMA-617 (225Ac-PSMA-617) in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With or Without Prior [ 177 Lu]Lu-PSMA (177Lu-PSMA) Radioligand Therapy (RLT) Abstract # 5020 Rapid Oral May 31, 4:30pm – 6:00pm CDT Abstract # 5010 Oral June 1, 3:00pm – 4:30pm CDT Scemblix (asciminib) ASC4FIRST wk 144 Analysis: Efficacy and Safety and Tolerability With Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed (ND) chronic myeloid leukemia in Chronic Phase (CML-CP) Abstract #6583 Poster June 1, 9:00am – 12:00pm CDT Kisqali (ribociclib) Prognostic and Predictive Impact of Baseline Gene Expression (Exp) in the NATALEE Trial of Adjuvant (Adj) Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in HR+/HER2− Early Breast Cancer (EBC) Abstract #501 Oral May 30, 1:15pm – 4:15pm CDT Real-World (RW) Post-Progression Outcomes Following First-Line (1L) Ribociclib (RIB) + Aromatase Inhibitor (AI) Versus AI Alone in African American and Low Socio-Economic Status (SES) Patients (Pts) With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) in the US Abstract #1073 Poster June 1, 1:30pm – 4:30pm CDT Real-World (RW) Post-Progression Outcomes After First-Line (1L) Treatment With Ribociclib + an Aromatase Inhibitor (AI) vs AI Alone in US Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) Abstract # e13044 Online publication Key EHA data highlights include: Abstract Title Abstract Number/ Presentation Details Scemblix (asciminib) ASC4FIRST wk 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Abstract # S160 Oral June 11, 4:45pm – 6:00pm CEST Ianalumab (VAY736) Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results From the VAYHIT2 Phase 3 Trial Abstract # PF1340 Poster June 12, 6:45pm – 7:45pm CEST Pelabresib (DAK539) Pelabresib Monotherapy in Myelofibrosis After Janus Kinase Inhibitor Failure: Results From Arm 1 of the Open-Label, Phase 2 MANIFEST Study Abstract # PS1987 Poster June 13, 6:45pm – 7:45pm CEST Rapcabtagene autoleucel (YTB323) Safety, Cellular Kinetics and Early Efficacy of Rapcabtagene Autoleucel (YTB323), a Rapidly Manufactured Autologous CD19 CAR-T Therapy, in Severe, Refractory Autoimmune Diseases Abstract # PF1241 Poster June 12, 6:45pm – 7:45pm CEST Fabhalta ® (iptacopan) Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from APPLY, APPOINT and roll-over extension program Abstract #PS1788 Poster June 13, 6:45pm – 7:45pm CEST Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program Abstract # PS1797 Poster June 13, 6:45pm – 7:45pm CEST Novartis in oncology The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients. As Novartis reimagines medicine, it collaborates with a wide range of patient advocacy groups and supports education, early cancer screening and diagnosis. With a broad research and development portfolio across solid tumors, hematology and radioligand therapy (RLT), Novartis is committed to using technology, leading science and patient-centered research to deliver pioneering cancer care for all those in need.